Go L.

Investor

📍 San Francisco Bay Area, United States🔄 Updated July 2026💼 3 investments📅 6 years investing🗓 Last invested Jan 2020
Angel investor🌍 United States
3
Total investments
0
Early stage
3
Mid stage
0
Late stage
6y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
2020
Ample is a great-tasting, complete meal replacement drink that combines the latest nutrition science with wholesome, real food ingredients—for a balanced meal in a bottle that makes it easy and fast to achieve optimal nutrition at your desk or on-the-go. “I see so many people feel challenged to incorporate healthy meals into their busy lives or even understand what is healthy.​ Our goal is to offer optimal nutrition thats completely simplified.” - Connor Young, Founder and CEO of Ample We believe that health, convenience, and great taste shouldnt be mutually exclusive. While most quick meal solutions are loaded with sugar, artificial sweeteners, and unbalanced nutrition, Ample provides an easy, real food meal in a bottle to help you eat optimally on your busiest days—or anytime you need a fast, healthy meal.
Angel Investor
2020
Unbanked is a global fintech solution built on blockchain. Predicated on the belief that financial access and control is a fundamental human right, Unbanked connects traditional enterprise, and banking systems with blockchain infrastructure, expanding the utility of cryptocurrency for investing and everyday purchases. We provide organizations and consumers with a suite of highly bespoke financial services like FDIC-insured bank accounts, debit cards, and rewards, which enable both the banked, unbanked, and underbanked to create a financial experience as unique as the life they live.
Angel Investor
2020
Delee is a medical device company that has developed two devices: the CytoCatch™ Isolation Platform and the CytoCatch™ Imaging System, for isolating and analyzing circulating tumor cells (CTCs) from patient blood samples. The isolation platform filters CTCs onto a membrane and stains them through an automated workflow for visualization, and analysis via the imaging system. This technology will help in the early detection of cancer while providing physicians with information to personalize each patient’s therapy and monitor its effectiveness throughout the course of their disease.
Experience · 4 entries
All (4)
Investments (3)
2020
Angel Investor
2020
Ample is a great-tasting, complete meal replacement drink that combines the latest nutrition science with wholesome, real food ingredients—for a balanced meal in a bottle that makes it easy and fast to achieve optimal nutrition at your desk or on-the-go. “I see so many people feel challenged to incorporate healthy meals into their busy lives or even understand what is healthy.​ Our goal is to offer optimal nutrition thats completely simplified.” - Connor Young, Founder and CEO of Ample We believe that health, convenience, and great taste shouldnt be mutually exclusive. While most quick meal solutions are loaded with sugar, artificial sweeteners, and unbalanced nutrition, Ample provides an easy, real food meal in a bottle to help you eat optimally on your busiest days—or anytime you need a fast, healthy meal.
Angel Investor
2020
Unbanked is a global fintech solution built on blockchain. Predicated on the belief that financial access and control is a fundamental human right, Unbanked connects traditional enterprise, and banking systems with blockchain infrastructure, expanding the utility of cryptocurrency for investing and everyday purchases. We provide organizations and consumers with a suite of highly bespoke financial services like FDIC-insured bank accounts, debit cards, and rewards, which enable both the banked, unbanked, and underbanked to create a financial experience as unique as the life they live.
Angel Investor
2020
Delee is a medical device company that has developed two devices: the CytoCatch™ Isolation Platform and the CytoCatch™ Imaging System, for isolating and analyzing circulating tumor cells (CTCs) from patient blood samples. The isolation platform filters CTCs onto a membrane and stains them through an automated workflow for visualization, and analysis via the imaging system. This technology will help in the early detection of cancer while providing physicians with information to personalize each patient’s therapy and monitor its effectiveness throughout the course of their disease.
2018
Redwood Capital
Partner
2018